Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
26,5 GBX | -3,64% | -11,67% | +70,97% |
18/04 | Renalytix chief business officer wordt president | AN |
18/04 | Renalytix plc kondigt wijzigingen in de leiding aan, met ingang van 30 april 2024 | CI |
Vakgebied
Aantal werknemers: 102
Verkoop per activiteit
GBP in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Artificial Intelligence-enabled in Vitro Diagnostics
100,0
%
| 2 | 100,0 % | 3 | 100,0 % | +26,61% |
Verkoop per regio
GBP in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United Kingdom
100,0
%
| 2 | 100,0 % | 3 | 100,0 % | +26,61% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 15-03-18 |
James Sterling
DFI | Director of Finance/CFO | 54 | 15-03-18 |
Thomas McLain
PSD | President | 66 | 29-07-19 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 15-03-18 |
Michael Donovan
CTO | Chief Tech/Sci/R&D Officer | 70 | 15-03-18 |
Joseph Hutson
PRN | Corporate Officer/Principal | - | 22-07-21 |
Sales & Marketing | - | 07-06-21 | |
Salim Hamir
SEC | Corporate Secretary | - | - |
Jed Fulk
SAM | Sales & Marketing | 64 | 07-10-21 |
Howard Doran
PRN | Corporate Officer/Principal | 63 | 01-09-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 74 | 30-08-21 |
Chairman | 72 | 15-03-18 | |
James McCullough
FOU | Founder | 56 | 15-03-18 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 15-03-18 |
Erik Lium
BRD | Director/Board Member | 56 | 01-11-18 |
Catherine Coste
BRD | Director/Board Member | 58 | 30-06-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 126 219 016 | 82 586 459 ( 65,43 %) | 0 | 65,43 % |
Bedrijfsgegevens
Sector
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+70,97% | 42,02 mln. | |
-12,06% | 19,18 mld. | |
-44,61% | 2,73 mld. | |
+16,10% | 1,84 mld. | |
-3,24% | 1,61 mld. | |
+20,19% | 1,18 mld. | |
-21,52% | 898 mln. | |
-8,03% | 710 mln. | |
-16,68% | 694 mln. | |
+13,21% | 526 mln. |
- Beurs
- Aandelen
- Koers RENX
- Onderneming Renalytix Plc